A Phase 3 interventional study of Lurasidone and Lurasidone in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 65 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-17.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 5th largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 9th registered.
3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2008.
This study's enrollment of 488 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 9 that started in 2008, is one of 21 in phase 3, and was the 9th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lurasidone
Drug: Lurasidone
Drug: Quetiapine XR
Drug: Placebo
Lurasidone 80 mg tablets
Lurasidone 4 40 mg tablets
Quetiapine XR 600mg
Matching Placebo to Lurasidone or Quetiapine
Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase
The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.
Time frame: Week 6
Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment
Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).
Time frame: 6-Weeks
| Milestone | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo |
|---|---|---|---|---|
| Started | 125 | 121 | 120 | 122 |
| Completed | 89 | 93 | 97 | 74 |
| Not completed | 36 | 28 | 23 | 48 |
The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.
| scores on a scale | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo |
|---|---|---|---|---|
| Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase | -22.2 (-25.7 to -18.7) | -26.5 (-30.0 to -23.0) | -27.8 (-31.3 to -24.2) | -10.3 (-13.9 to -6.7) |
Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).
| scores on a scale | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo |
|---|---|---|---|---|
| Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment | -1.5 (-1.7 to -1.3) | -1.7 (-1.9 to -1.5) | -1.7 (-1.9 to -1.5) | -0.9 (-1.1 to -0.7) |
Collected over 14 days post study therapy. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 80 mg | — | 1/125 (0.8%) | 71/125 (56.8%) |
| Lurasidone 160 mg | — | 4/121 (3.3%) | 76/121 (62.8%) |
| Quetiapine XR 600mg | — | 1/119 (0.8%) | 70/119 (58.8%) |
| Placebo | — | 4/121 (3.3%) | 69/121 (57%) |
| Event | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo |
|---|---|---|---|---|
| Left Ventricular DysfunctionCardiac disorders | 1/125 | 4/121 | 1/119 | 4/121 |
| Pyschotic DisorderPsychiatric disorders | 0/125 | 0/121 | 1/119 | 2/121 |
| Suicidal IdeationPsychiatric disorders | 0/125 | 0/121 | 0/119 | 2/121 |
| Hepatitis ViralInfections and infestations | 0/125 | 0/121 | 1/119 | 0/121 |
| Abdominal Hernia ObstructiveGastrointestinal disorders | 0/125 | 1/121 | 0/119 | 0/121 |
| Non-cardiac Chest PainGeneral disorders | 0/125 | 1/121 | 0/119 | 0/121 |
| Hand FractureInjury, poisoning and procedural complications | 0/125 | 1/121 | 0/119 | 0/121 |
| AgressionPsychiatric disorders | 0/125 | 0/121 | 0/119 | 1/121 |
| SchizophreniaPsychiatric disorders | 0/125 | 1/121 | 0/119 | 0/121 |
| Suicidal BehaviorPsychiatric disorders | 0/125 | 0/121 | 0/119 | 1/121 |
| Event | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo |
|---|---|---|---|---|
| DizzinessNervous system disorders | 6/125 | 7/121 | 16/119 | 2/121 |
| SomnolenceNervous system disorders | 5/125 | 8/121 | 16/119 | 1/121 |
| InsomniaPsychiatric disorders | 14/125 | 8/121 | 5/119 | 11/121 |
| HeadacheNervous system disorders | 12/125 | 12/121 | 13/119 | 13/121 |
| AgitationPsychiatric disorders | 4/125 | 6/121 | 3/119 | 10/121 |
| AnxietyPsychiatric disorders | 9/125 | 4/121 | 1/119 | 10/121 |
| NauseaGastrointestinal disorders | 10/125 | 8/121 | 4/119 | 4/121 |
| AkathisiaNervous system disorders | 10/125 | 9/121 | 2/119 | 1/121 |
| Dry MouthGastrointestinal disorders | 2/125 | 2/121 | 9/119 | 1/121 |
| VomitingGastrointestinal disorders | 8/125 | 9/121 | 6/119 | 6/121 |
| Age, Continuous(years) | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 36.2 ± 10.9 | 37.9 ± 11.3 | 37.4 ± 10.4 | 37.4 ± 10.8 | 37.2 ± 10.8 |
| Gender(participants) | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 29 | 39 | 42 | 44 | 154 |
| Male | 96 | 82 | 77 | 77 | 332 |
| Region of Enrollment(participants) | Lurasidone 80 mg | Lurasidone 160 mg | Quetiapine XR 600mg | Placebo | Total |
|---|---|---|---|---|---|
| United States | 40 | 37 | 35 | 39 | 151 |
| Ukraine | 19 | 20 | 19 | 17 | 75 |
| Romania | 13 | 11 | 13 | 12 | 49 |
| Russian Federation | 22 | 22 | 21 | 22 | 87 |
| India | 24 | 25 | 25 | 24 | 98 |
| Colombia | 7 | 6 | 6 | 7 | 26 |
The record gives a start of Oct 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →